The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review

Qingyan Chen, Jiaojiao Zhao, Yifei Wang, Long Ge, Joey Sum-Wing Kwong, Junjie Lan, Rui Zhang, Huaye Zhao, Linfang Hu, Jiaxue Wang, Shuimei Sun, Songsong Tan, Xiaoqing Lin, Rui He, Wenyi Zheng, Xiaosi Li, Jiaxing ZhangFrontiers in Pharmacology 2025 · DOI

Abstract: PROSPERO CRD42023407632.

Introduction

Invasive aspergillosis (IA) is a severe fungal infection that primarily affects immunocompromised individuals, such as organ transplant recipients or patients undergoing intensive chemotherapy. Historically, IA has been associated with high mortality rates, often reaching 80%–90% in high-risk populations. While several antifungal agents, particularly from the triazole class, have been developed, clinicians often face a "choice overload" due to a lack of direct, head-to-head clinical trials comparing all available first-line options.

This systematic review and network meta-analysis (NMA) aims to address this gap by synthesizing existing trial data to determine the most effective and safest monotherapy for the primary treatment of IA.

Methods

The researchers conducted a systematic review and a frequentist network meta-analysis (NMA) to evaluate various antifungal treatments. They searched major global and Chinese databases, including PubMed, Embase, and CNKI, for randomized controlled trials (RCTs) published through July 2023.

PRISMA flow diagram of the study selection process.

Unlike standard meta-analyses that only compare two groups directly, the NMA utilized a random-effects model to perform indirect comparisons across multiple treatments. The quality of evidence was assessed using the GRADE approach, and treatments were ranked using Surface Under the Cumulative Ranking Area (SUCRA) values, where a higher percentage indicates a greater probability of a treatment being the most effective.

Study Selection and Datasets

The systematic search identified four studies that met the inclusion criteria, involving a total of 1,368 participants. These trials focused on patients with "proven," "probable," or "possible" IA according to EORTC/MSG criteria. Key trials included comparisons of Voriconazole vs. Amphotericin B (Herbrecht et al.), Isavuconazole vs. Voriconazole (Maertens et al., 2016), and Posaconazole vs. Voriconazole (Maertens et al., 2021).

Key Results and Insights

The analysis confirms a significant shift in the treatment landscape, favoring modern triazoles over the traditional gold standard, amphotericin B deoxycholate (D-AmB).

Network plots illustrating the direct and indirect comparisons between antifungal treatments.

Efficacy and Mortality

  • Triazole Supremacy: All evaluated triazoles—isavuconazole (ISA), voriconazole (VCZ), and posaconazole (POS)—demonstrated superior overall response rates compared to D-AmB. For instance, Voriconazole nearly doubled the likelihood of a successful response compared to D-AmB (RR = 1.95).
  • Isavuconazole’s Performance: For patients with "proven and probable" IA, isavuconazole emerged as the top performer for mortality reduction, achieving a dominant SUCRA score of 93.50%. Compared to D-AmB, isavuconazole reduced the risk of death at week 12 by nearly half (RR = 0.52, 95% CI 0.31–0.86).
  • Diagnostic Sensitivity: The optimal drug choice varied slightly based on diagnostic certainty. In broader groups that included "possible" IA cases, posaconazole showed the highest probability of being the most effective for reducing mortality (SUCRA 74.70%).

Safety Profiles

Safety was a major differentiator between treatment classes. D-AmB was associated with a significantly higher risk of severe adverse events (SAEs), particularly nephrotoxicity. While the safety profiles of the three triazoles were generally comparable, isavuconazole is noted in broader literature for having fewer skin and eye-related side effects than voriconazole.

Limitations and Future Directions

Despite the rigorous methodology, the study has several limitations:

  • Limited Trial Data: The NMA is based on a small number of primary trials, which can limit statistical power and the overall "connectedness" of the network.
  • Monotherapy Focus: The review excluded combination therapies, which are sometimes used in clinical practice for severe cases.
  • Amphotericin B Formulations: The comparisons were made against the older, more toxic deoxycholate formulation of amphotericin B, rather than the more modern liposomal versions (e.g., AmBisome) commonly used today.

Future research should focus on more head-to-head RCTs to refine these rankings and incorporate newer antifungal agents as they become available in the clinical market.

Summary updated

Abstract

PROSPERO CRD42023407632.
BibTeX
@inproceedings{chen2025efficacy,
  author = {Qingyan Chen and Jiaojiao Zhao and Yifei Wang and Long Ge and Joey Sum-Wing Kwong and Junjie Lan and Rui Zhang and Huaye Zhao and Linfang Hu and Jiaxue Wang and Shuimei Sun and Songsong Tan and Xiaoqing Lin and Rui He and Wenyi Zheng and Xiaosi Li and Jiaxing Zhang},
  title = {{The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2024.1530999},
}
Figure